Guardant Health gets CE marking for Guardant360 CDx with AstraZeneca’s camizestrant

Guardant Health said Guardant360 CDx received CE marking under Europe’s in vitro diagnostic medical devices regulation as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in advanced ER-positive, HER2-negative breast cancer.